Results From 10-Patient Case Study Lead to Phase III Clinical Trial for Patients with Duchenne Muscular Dystrophy
Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with
Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.
Muscle weakness begins in early childhood, often causing deformity of the arms, legs and spine. Heart and respiratory muscles often begin to fail before children reach early teen years. Although steroid medications – which often are not well tolerated – and other therapies may ease symptoms and delay the most severe effects, no disease-specific treatment exists, and patients rarely survive into their 30s.
But in this case study of 10 boys with Duchenne muscular dystrophy, also called DMD, a single dose of a drug often prescribed for erectile dysfunction or pulmonary hypertension corrected defective blood vessel mechanisms and restored blood flow to exercising muscles.
“The effects were immediate and dramatic, raising the question: If a single dose restores blood flow to muscle while the drug is in the patient’s system, could ongoing tadalafil administration provide sustained benefits, possibly preserve muscle and slow disease progression? If so, this would offer a new therapeutic strategy for DMD, and we have launched a randomized Phase III clinical trial to find out,” said Ronald Victor, MD, director of the Cedars-Sinai Center for Hypertension, associate director of clinical research at the Heart Institute and the Burns and Allen Chair in Cardiology Research. He is the senior author of a highlighted article in the May 7 online edition of Neurology.
Duchenne muscular dystrophy results from a genetic defect that eliminates a protein called dystrophin in the membranes of muscle cells. For more than 25 years, Victor has studied DMD and a less aggressive but debilitating variant called Becker muscular dystrophy. This form of muscular dystrophy, usually diagnosed in early adulthood, is caused by a reduction, but not absence, of dystrophin.
Victor led a research team that in 2000 discovered that the blood flow abnormality in the muscles of children with DMD was caused by a loss of nitric oxide, a signaling chemical that normally tells blood vessels to relax during exercise, increasing blood flow and oxygenation.
In studies of mice bred to represent diseases of dystrophin deficiency, the researchers found that drugs prescribed for other disorders of blood vessel function could restore muscle blood flow and enable the animals to exercise more, with less muscle injury. Tadalafil, known by the brand names Cialis and Adcirca, and sildenafil, called Viagra and Revatio, have long been approved by the Food and Drug Administration to treat erectile dysfunction and pulmonary hypertension, a serious illness that restricts blood flow to the lungs.
Translating these findings to a human clinical trial, Victor and his colleagues published in 2012 a study showing that tadalafil fully restored blood flow in eight of nine patients with Becker muscular dystrophy.
In the new study, investigators found that when boys with Duchenne muscular dystrophy performed handgrip exercises, the major artery of the arm and the blood vessels in muscles of the forearm failed to respond the way they did in healthy boys of similar ages, 8 to 13. But when the boys with DMD were given a single dose of tadalafil, normal vessel function and blood flow were restored. Similar results occurred when sildenafil, a drug with a similar mechanism of action on vessels but a different chemical structure, was used in place of tadalafil.
“Steroids and cardiac-protective blood pressure medication are increasingly prescribed at early ages for patients with Duchenne muscular dystrophy in an effort to delay by a few years the most devastating effects of the disease. But these treatments have no effect on the blood vessel dysfunction that prevents muscles from getting the oxygen they need,” said Victor. “In contrast, in our study, a single dose of tadalafil or sildenafil had an immediate effect. These are well-studied, well-tolerated drugs that are already on the market. If additional study confirms their benefits, repurposing the drugs for muscular dystrophy patients could quickly transform clinical practice.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- CUREDUCHENNE STRENGTHENS RESEARCH AND INVESTMENT TEAM WITH ADDITION OF VICE PRESIDENT OF RESEARCH AND PARTNER OF CUREDUCHENNE VENTURESon May 13, 2022 at 3:10 pm
CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy (DMD), today announced the promotion of Lianna Orlando, PhD, to Vice President of ...
- FDA grants orphan drug designation for Duchenne muscular dystrophy treatmenton May 12, 2022 at 12:20 pm
Please provide your email address to receive an email when new articles are posted on . Stealth BioTherapeutics Corp. announced that the FDA has granted orphan drug designation to elamipretide for the ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophyon May 12, 2022 at 5:07 am
Pre-IND meeting request granted by FDA's Division of Neurology IBOSTON, May 12, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Helen DeVos Children's Hospitalon May 11, 2022 at 7:34 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with 1st Clinic in Michigan WASHINGTON, May 11, 2022 ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Helen DeVos Children's Hospitalon May 11, 2022 at 7:27 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with 1st Clinic in Michigan HDVCH is a growing center and ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Helen DeVos Children’s Hospitalon May 11, 2022 at 7:19 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with 1st Clinic in Michigan WASHINGTON, May 11, 2022 /PRNewswire/ - ...
- Muscular dystrophy startup goes public in $108M IPOon May 6, 2022 at 10:05 am
Founded in 2018, PepGen is developing ogleonucleotide medicines for neurodegenerative diseases, with an initial focus on Duchenne muscular dystrophy and myotonic dystrophy Type 1. Its lead drug ...
- Duchenne Muscular Dystrophy Treatment Market Size, Share, Revenue, Segment & Forecast To 2030on May 5, 2022 at 4:06 am
The global Duchenne muscular dystrophy treatment market is estimated to grow at a CAGR of ~11% over the forecast period, i.e., 2022 – 2030. The ma ...
- Daily steroids safe and slows progression of duchenne muscular dystrophy, study suggestson May 4, 2022 at 1:10 pm
New research recommends daily steroid doses for children with Duchenne muscular dystrophy, marking a significant change in how the disease is treated.
via Bing News